Prof Shahneen Sandhu
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
257 Scholarly works
4 Projects
HIGHLIGHTS
2026
Journal article
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
DOI: 10.1016/S1470-2045(26)00017-32026
Journal article
Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer.
DOI: 10.1158/1078-0432.CCR-25-40012026
Journal article
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma
DOI: 10.1016/j.annonc.2025.10.12372025
Journal article
Consensus guidelines for antibacterial prophylaxis in patients with neutropenia
DOI: 10.1111/imj.702502025
Journal article
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer
DOI: 10.1038/s41467-025-60654-z2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2018
Research Grant
A Novel Strategy for Targeting Castrate-Resistant Prostate Cancer
RECENT SCHOLARLY WORKS
2025
Journal article
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
DOI: 10.2967/jnumed.125.2708042025
Journal article
Microbiota-derived butyrate promotes a FOXO1-induced stemness program and preserves CD8 T cell immunity against melanoma
DOI: 10.1016/j.immuni.2025.10.0042025
Journal article
1694eP Real-world induction targeted therapy (TT) with immune checkpoint inhibitor (ICI) therapy switch in advanced BRAF-mutant melanoma: A multi-institutional study
DOI: 10.1016/j.annonc.2025.08.23212025
Journal article
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
DOI: 10.1016/S1470-2045(25)00339-02025
Journal article
1636P Gonadal toxicity in men receiving immune checkpoint inhibitors for melanoma
DOI: 10.1016/j.annonc.2025.08.2264
RECENT PROJECTS
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Strategies for Psma-Negative Disease
2019
Internal Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease